Abbott stock tests pivotal support at $101.82 with mixed technical signals: weekly analysis

Traders Union
All News
Stocks
Abbott Laboratories gains 2.57% this week

Highlights

Shares of Abbott gained 2.57% over the past week but remain below both the 50-day and 200-day moving averages.
Key technical signals are mixed, with momentum indicators split and Stochastic RSI showing the stock is overbought.
Trading is expected between $99.23 and $104.76 in the next five days, anchored by support at $101.82 and resistance at $103.12.

Product launches and FDA approvals drive growth outlook and bolster sentiment

Abbott advanced its product lineup with the launch of Ensure Max Protein 3-in-1 Muscle Support, targeting performance-focused consumers, according to Yahoo Finance. The company also began U.S. commercialization of the SimpleScreen CRC blood-based colorectal cancer screening test and gained FDA approval for expanded CardioMEMS HF System app capabilities, as reported by Simply Wall St. These moves reinforce ABT’s focus on growth across its nutrition, diagnostics, and medical devices businesses, while its longstanding dividend record continues to attract income-oriented investors (source: Simply Wall St). The next scheduled event is ABT’s third-quarter 2026 earnings report on October 21, with analysts expecting year-over-year gains in earnings and revenue, TradingView noted.

Volatility rises as momentum indicators give conflicting technical signals

On the daily chart, structure remains in flux as volatility reached 6.37% this week and the move higher shows an emerging character that is not yet confirmed. Momentum signals offer mixed messages, with the MACD pointing to continued selling while ADX at 20.44 suggests a possible upward trend, and the Stochastic RSI is firmly overbought at 100. Immediate support is provided by the Ichimoku Kijun at $101.82, which the stock is currently holding, while resistance is defined by the MA-200 at $103.12. These nearby levels are likely to determine direction in the days ahead.

Upside bias prevails this week with pivotal range defined by key levels

Over the next five trading days, the expected range for Abbott is $99.23 to $104.76. There is a 62% probability of an increase and a 38% probability of a decrease. The base case is for the stock to fluctuate between support at $101.82 and resistance at $103.12. Should price break above $103.12, a retest of the $104.76 upper boundary is in view. If support at $101.82 fails, a decline toward the $99.23 lower edge of the forecast range becomes likely.

Viktoras Karapetjanc, expert at Traders Union, sees this week’s 2.6% gain in Abbott Laboratories stock as setting the stage for fresh opportunity. He notes that innovation in nutrition and diagnostics, plus the expanded CardioMEMS HF System app approval, reinforce strong fundamental support behind the current advance. Momentum indicators now flash mixed signals, but the base case remains bullish as long as shares respect daily support at $101.82 and aim toward resistance at $103.12. With a 62% probability of further gains and robust product news, the analyst expects the bullish structure to remain intact. "With new product launches and solid backdrop, I am confident Abbott shares can test $104.76 in the coming week if current momentum holds."

Earlier, analysts noted that Abbott's upward moves had been constrained by persistent resistance despite positive product developments, with technical momentum remaining mixed. The current setup maintains this cautious outlook, as ongoing volatility and overbought signals mean traders should closely monitor the $101.82-$103.12 range for signs of a sustained directional breakout or breakdown.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.